PDE1 inhibitor compounds

A compound of Formula II:

• wherein
• (i) Q is —C(═O)—, —C(═S)—,
• (ii) R1 is C1-6alkyl;
• (iii) R2 is
• C1-6alkyl wherein said alkyl group is optionally substituted with one or more halo or hydroxy;
• (iv) R3 is
• 1) attached to one of the nitrogens on the pyrazolo portion of Formula II and is a moiety of Formula A
• wherein:
• X, Y and Z are, independently, N or C,
• R8, R9, R11 and R12 are independently H or halogen;
• and
• R10 is
• aryl or heteroaryl,
• wherein said aryl, heteroaryl, is optionally substituted with one or more C1-6alkyl, halogen, haloC1-6alkyl, hydroxy, carboxy, —SH, or an additional aryl or heteroaryl;
• provided that when X, Y or Z is nitrogen, R8, R9 or R10, respectively, is not present;
• (v) R4 is:
• C1-6alkyl,
• C3-8cycloalkyl,
• C3-8heterocycloalkyl,
• —C0-6alkylaryl or
• C0-6alkylheteroaryl
• wherein said aryl or heteroaryl is optionally substituted with one or more halo, hydroxy, C1-6alkyl, C1-6alkoxy or another aryl group;
• in free or salt form, provided that said compound is not:
• (a) 7-[(2,4-dichlorophenyl)methyl]-3-ethoxy-2,5-dimethyl-2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione;
• (b) 7-[(4-chlorophenyl)methyl]-3-ethoxy-2,5-dimethyl-2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione;
• (c) 2-[(2,5-dichlorophenyl)methyl]-3-ethoxy-5,7-dimethyl-2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione;
• (d) 2-[(4-bromophenyl)methyl]-3-ethoxy-5,7-dimethyl-2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione;
• (e) 3-[(4-methoxyphenyl)methoxy]-2,5,7-trimethyl-2H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione;
• (f) 1-[(3-bromophenyl)methyl]-5,7-dimethyl-3-(2-propen-1-yloxy)-1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione.